Freedom Capital Markets Maintains Buy on Nutex Health, Raises Price Target to $306

Freedom Capital Markets analyst Gene Mannheimer has maintained a Buy rating on Nutex Health (NASDAQ: NUTX) and raised the price target from $280 to $306.